MyMD’s Synthetic Cannabidiol Reduces Acute Inflammatory Pain in Preclinical Studies

MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) has announced results from a preclinical study of its investigational cannabinoid Supera-CBD™. Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain relief lasting up to five hours.

Chris Chapman, MD, president, director and chief medical officer, MyMD, said, “These preclinical results illustrate the potential of Supera-CBD to alleviate acute inflammatory pain related to injuries, burns, surgery, and flare-ups from chronic inflammatory conditions such as diabetic neuropathy and shingles.”

Highlights

MyMD says that Supera-CBD has a potential role in managing addiction, anxiety, chronic pain and seizures, as well as having anti-inflammatory effects.

Supera-CBD™ is a synthetic, non-toxic cannabidiol (CBD) analog that is an 8000-times more potent CB2 agonist than plant-based CBD.

Acute pain related to inflammation, burns, and nerve-related pain affects countless individuals worldwide. The global market for pain management was valued at around $36 billion in 2021 and is expected to reach $52 billion by 2026.

Supera-CBD™ is covered by Japanese Patent No. 7293561 B2, as a new molecular entity, in pharmaceutical formulations, and for use in therapeutic treatments. The Company has a total of 23 issued patents worldwide.

About MyMD Pharmaceuticals

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. MyMD’s lead clinical candidate, MYMD-1®, is an orally available next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated. MYMD-1®, with its small molecule design, improved safety profile and ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-α inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases. The company has completed Phase 2 studies of MYMD-1® for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications.

MyMD’s second therapeutic candidate is Supera-CBD, a novel, synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times more potent a CB2 agonist (activator) than plant-based CBD. In addition to its potential role in managing addiction, anxiety, chronic pain and seizures, Supera-CBD has also been shown to have anti-inflammatory effects. For more information, visit www.mymd.com.